Biological
Ad26COVS1 clinical trials
Also written Ad26.COV2.S and JNJ-78436735.
- studies test it
- 17
- open now
- 0
- in phase 3
- 6
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
17 studies that test it; most in 2021 (11)
| Year | Studies |
|---|---|
| 2020 | 5 |
| 2021 | 11 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 9
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 6
Janssen Vaccines & Prevention B.V. (10) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ANRS, Emerging Infectious Diseases (1) · Janssen Pharmaceutical K.K. (1) · Giselle Guerra (1) · Medical University of Vienna (1) · Instituto de Investigación Marqués de Valdecilla (1)
Often tested with
Tested in the same studies.
BNT162 Vaccine (3) · 2019-nCoV Vaccine mRNA-1273 (2) · Elasomeran/Davesomeran (1) · Mycophenolic Acid (1) · Methotrexate (1) · BNT162b5 (1)
Studies
Open first, then newest update. How each study uses Ad26COVS1 is read from its arms, and is right about nine times in ten.
Testing it · 17
- COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05000216Written as Ad26.COV2.S
- A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)CompletedPhase 2Janssen Vaccines & Prevention B.V.NCT04765384Written as Ad26.COV2.S
- A Study of Ad26.COV2.S and Influenza Vaccines in Healthy AdultsCompletedPhase 3Janssen Vaccines & Prevention B.V.NCT05091307Written as Ad26.COV2.S
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT04889209Written as Ad26.COV2.S
- A Study of Ad26.COV2.S in Adults (COVID-19)CompletedPhase 1/2Janssen Vaccines & Prevention B.V.NCT04436276Written as Ad26.COV2.S
- A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years InclusiveCompletedPhase 2Janssen Vaccines & Prevention B.V.NCT05007080Written as Ad26.COV2.S
- A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in AdultsCompletedPhase 3Janssen Vaccines & Prevention B.V.NCT04614948Written as Ad26.COV2.S
- A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult ParticipantsCompletedPhase 3Janssen Vaccines & Prevention B.V.NCT04505722Written as Ad26.COV2.S
- A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy AdultsCompletedPhase 3Janssen Vaccines & Prevention B.V.NCT04908722Written as Ad26.COV2.S
- A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2CompletedPhase 2Janssen Vaccines & Prevention B.V.NCT04999111Written as Ad26.COV2.S
- COVID-19 3rd Dose Vaccine in Transplant PatientsTerminatedPhase 3Giselle GuerraNCT05047640Written as JNJ-78436735 Vaccine
- Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 VaccineActive, not recruitingPhase 2ANRS, Emerging Infectious DiseasesNCT05409261Written as Ad26.COV2.S
- A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and AdolescentsCompletedPhase 2Janssen Vaccines & Prevention B.V.NCT04535453Written as Ad26.COV2.S
- Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.WithdrawnPhase 3Instituto de Investigación Marqués de ValdecillaNCT05048940Written as Janssen vaccine
- Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant RecipientsStatus unknownPhase 2Medical University of ViennaNCT05324319Written as Ad26COVS1
- A Study of Ad26.COV2.S in Healthy Adults (COVID-19)CompletedPhase 1Janssen Vaccines & Prevention B.V.NCT04894305Written as Ad26.COV2.S
- A Study of Ad26.COV2.S in Adults (COVID-19)CompletedPhase 1Janssen Pharmaceutical K.K.NCT04509947Written as Ad26.COV2.S
Codes
What other systems call Ad26COVS1 · ClinicalTrials.gg INT006859
- MeSH (NLM) D000090984Ad26COVS1One source NLM
- UNII (FDA) JT2NS6183BAD26.COV2.SConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000090984 | Ad26COVS1 | One source NLM |
| UNII (FDA) | JT2NS6183B | AD26.COV2.S | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.